Memic Innovative Surgery Raises $96 Million

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

AAOS on IPO Elimination Reversal in 2022 CMS Outpatient Rule

AAOS is encouraged to hear that CMS has heeded the patient safety concerns of the physician community regarding the abrupt elimination of the Inpatient Only.

Stryker Steps up to the Plate at Chickasaw Bricktown Ballpark with Its SmartRobotics™ Technology

Stryker, the Official SmartRobotics™ Joint Replacement Partner of Minor League Baseball, showcases its Mako SmartRobotics™ Technology to Oklahoma City Dodgers fans.

April 12, 2021

Memic Innovative Surgery notes the funding primarily supports the commercialization of Hominis® surgical robot in the United States following FDA De Novo marketing authorization. (The financing round was led by Peregrine Ventures and Ceros with participation from Ourcrowd and Accelmed).

The financing will also support continued research and development efforts including expanding the company’s portfolio of products and manufacturing scaleup, as well as provide world-class customer support and training.

“The Hominis system represents a significant advancement in the growing multi-billion-dollar robotic surgery market. This financing positions us to accelerate our commercialization efforts and bring Hominis to both surgeons and patients in the months ahead,” said Dvir Cohen, co-founder and CEO of Memic.

The Hominis system received De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) in February 2021 for use in single site, natural orifice laparoscopic-assisted transvaginal benign surgical procedures including benign hysterectomy. It is the first and only FDA-authorized surgical robotic platform that features miniature humanoid-shaped robotic arms that provide human level dexterity, multi-planar flexibility and 360 degrees of articulation. The biomimetic instruments are designed to replicate the motions and capabilities of a surgeon’s arms, with shoulder, elbow and wrist joints. Multiple instruments can be introduced to the body through a single portal and the 360-degree articulation offers obstacle avoidance as well as optimal access and working angles.

In addition to these features, the system will be sold at a significantly lower price compared to other marketed robotic surgery systems, potentially allowing more medical facilities including hospitals and ambulatory surgical centers to access and adopt surgical robotics.

“Given the broad potential of Hominis combined with a strong management team, we are proud to support Memic and execution of its bold vision,” said Eyal Lifschitz, managing general partner of Peregrine Ventures.

“We are grateful for the opportunity to work with management on this exciting milestone for both Memic and the field of robotic surgery,” said Mark Goldwasser, CEO of Ceros.

spot_img

DON'T MISS

Dr. Woodrow Myers Joins the Freespira Board of Directors

Former Blue Cross Blue Shield Health Plan chief medical officer and chief healthcare strategist brings clinical, quality and business insights to fast-growing digital therapeutic company.

Avanos Medical, Inc. Appoints Moji James as Senior Vice President & General Counsel

Prior to Tmunity, James served as senior vice president and general counsel of Iroko Pharmaceuticals, and she began her life sciences legal career at Wyeth Pharmaceuticals (now part of Pfizer).

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.